Overcoming Gene Editor Delivery Challenges to Maximize Translational Success
Time: 2:00 pm
day: Day Two 12th
Details:
- Explore methodologies to assess safety and efficacy in preclinical models and highlight the importance of early-stage validation to mitigate risks and optimize translational success
- Share progress in developing a non-viral, engineered ribonucleoprotein (eRNP) CRISPR gene editor platform enabling safe and effective gene modification via subretinal administration
- Examine strategies to navigate translational challenges in ophthalmic disorders and discuss how we are working toward overcoming model limitations